Actinium Pharmaceuticals, Inc.
ATNM · XNYSCIK 1388320fmd_18663XMBB5PNAD5PRP2E594NB1制造业 · 医药制剂模板: 标准
覆盖范围: 2001年1月01日 至 2026年6月30日，共 73 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | 1 | 1 | 0 | – | 0 |
| 营业成本 | – | – | – | – | – | 1 | – | – | – | – |
| 净利息收入 | (0) | 0 | 0 | 0 | 0 | 0 | 1 | 3 | – | – |
| 毛利润 | – | – | – | – | – | 0 | – | – | – | – |
| 研发费用 | 18 | 18 | 17 | 17 | 16 | 18 | 23 | 39 | 30 | 21 |
| 营业费用合计 | 27 | 27 | 24 | 22 | 22 | 26 | 35 | 52 | 42 | 36 |
| 营业利润 | (27) | (27) | (24) | (22) | (22) | (25) | (34) | (52) | (42) | (36) |
| 利息费用 | 0 | – | – | – | – | – | – | – | – | – |
| 利息及投资收益 | – | – | – | – | – | – | – | 3 | 4 | 2 |
| 其他营业外收入（支出） | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 2 |
| 税前利润 | – | – | – | – | – | – | – | – | – | (34) |
| 所得税费用 | – | – | – | – | – | – | – | – | – | – |
| 净利润 | (24) | (27) | (24) | (22) | (22) | (25) | (33) | (49) | (38) | (34) |
| 归属于普通股股东的净利润 | – | – | (24) | (22) | (22) | (25) | – | – | – | – |